Edwards Lifesciences Navigates Slower TAVR Growth With Adoption of TMTT Valves
Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...
Hosted on MSN17h
Edwards Makes A Bullish Move As Heart-Valve Replacements Top $1 Billion
Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.
The Times of Northwest Indiana19h
Get Healthy: Wearables, noninvasive procedures improving the way heart conditions are treated
As tools become more precise and non-invasive, doctors are able to diagnose and treat heart conditions with greater accuracy and efficiency.
Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to ...